# Atlas Molecular Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atlas-molecular-pharma

- Industry: Biotechnology
- Headquarters: Derio, Spain
- Website: www.atlasmolecularpharma.com/
- Latest round: Seed (Jan 1, 2016)
- Investors on record: 1

## About

Based in Bizkaia, Spain, and founded in 2015, Atlas Molecular Pharma, a Spin-off of the CIC-Biogune research center, operates as a pharmaceutical research and development company that for the treatment of rare and ultra-rare metabolic diseases. In January 2026, Atlas Molecular Pharma raised EUR 5.5 million in equity and grant funding led by Inveready Asset Management, with participation Center for Technological & Industrial Development, Kereon Partners, Gestion de Capital Riesgo del Pais Vasco, Endometrial DIDI, CRB Inverbio, and U.S. Food and Drug Administration.

The firm develops its proprietary technology called Chassys ™ which is an NMR-based technology that develops therapies to correct the phenotype for a range of rare diseases. The firm offers disease-specific pharmacological chaperones for diseases like congenital erythropoietic porphyria, prion diseases, and tyrosinemia type I.

The company will use the January 2026 funding to advance the clinical development of ATL-001 through a Phase I-II trial.

## Funding rounds

- Seed, Jan 1, 2016 — Kereon Partners

## Investors

- Kereon Partners (https://capitalatlas.ai/funds/kereon-partners) — Seed